Trial Profile
Phase II Trial Of TAXOTERE + TARCEVA To Treat HRPC In Men ≥ 65 Years Of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 25 Jun 2010 Actual patient number (1) added as reported by ClinicalTrials.gov.
- 25 Jun 2010 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
- 25 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.